STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (June 2018)

23 slides from STRATA Skin Sciences's investor presentation, Jun 20, 2018

  1. Slide 1: June 2018 Investor Presentation: Driving Value to Dermatology Partners

    June 2018 Investor Presentation Driving Value to Dermatology Partners Matching Patients and Clinics

  2. Slide 2: Safe Harbor Statement

    This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking s

  3. Slide 3: STRATA Investment Highlights

    STRATA Investment Highlights Seasoned Management Team – Experienced in the BusinessDr. Dolev Rafaeli, CEO returns with the Accelmed transaction Excimer Laser Technology for DermatologyPsoriasis, Vitiligo, Eczema, Atopic Dermatitis and Leukoderma Large Market Opportunity Over 35 Million patients in t

  4. Slide 4: XTRAC Revenue Growth Strategy

    XTRAC Revenue Growth Strategy 8n6 Protocol Treatment *RDX – Reimbursement Database XTRAC (proprietary system) REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY V

  5. Slide 5: XTRAC DTC Advertising

    XTRAC DTC Advertising Vary ye Psori: © acatasa 300-874-8762 Usektrac.com XTRAC = STRATA

  6. Slide 6: Lead Generation is a Business Driver

    Lead Generation is a Business Driver Patient leads in one quarterLeads turn into appointmentsAppointments lead to XTRAC partner revenueOther revenue for the partner clinicRevenue for STRATA 6

  7. Slide 7: DTC Initial Results – Reduced Acquisition Costs

    DTC Initial Results – Reduced Acquisition Costs Total Likes Total Reach 7

  8. Slide 8: The Market Opportunity

    The Market Opportunity XTRAC cleared in four indications PsoriasisVitiligoEczema and Atopic DermatitisLeukodermaOver 35 million domestic patients3 CPT codes ($150 - $250 based on BSA)$170 average reimbursement rate per treatmentClinical Protocol – 6.2 treatments to PASI 75 Average of 23 treatments p

  9. Slide 9: Excimer Laser Technology - XTRAC/VTRAC

    Excimer Laser Technology - XTRAC®/VTRAC® TechnologyXTRAC excimer laser uses highly targeted (308nm) beam of UVB light to treat affected skin area without damaging surrounding tissueVTRAC is a lamp based 308nm laserTreatment avoids side effects and cost of biologics, and messy topicalsTreatments are

  10. Slide 10: How XTRAC Works

    How XTRAC Works After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UV light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 140+ peer reviewed published clinical studies 10

  11. Slide 11: Domestic Market: Installed Base Overview

    Domestic Market: Installed Base Overview 750 Partner XTRAC 138 sold XTRAC 4 Regions 22 Territories 15 Field Service In-house call center 11

  12. Slide 12: International Market: Installed Base

    International Market: Installed Base OUS sales are through distribution with no current recurring revenue model appliedMajor Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher that domestic market1,186 OUS devices sold and in service Strategic Growt

  13. Slide 13: Turnaround Strategy

    Turnaround Strategy DOMESTIC MARKET OUS MARKETS Enhance technology offeringExpand geographical reach in certain markets Rebuild XTRAC value proposition for partner physician accountsDTC is a revenue driver: Online and offline advertisement, in-house call centerPatient Communication: For both referra

  14. Slide 14: May 2018: Transformative Transaction

    May 2018: Transformative Transaction 2013 2014 2015 2016 2017 2012 Based on STRATA 10-k Annual Report; Dec 31, 2017* STRATA bought XTRAC business from PhotoMedex in 2015 Average Treatment Revenue Per Laser By Quarter 14

  15. Slide 15: Media Spend to XTRAC Treatment Revenue: The Opportunity

    Media Spend to XTRAC Treatment Revenue: The Opportunity Based on STRATA and PhotoMedex Investor Presentations* STRATA bought XTRAC business from PhotoMedex in 2015 15

  16. Slide 16: Optimal Therapeutic Dose (OTD) – 510(k) Submitted for MMD

    Optimal Therapeutic Dose (“OTD”) – 510(k) Submitted for MMDThe Path to Optimal Clinical Outcomes and Patient Retention MECHANISMTip applies 4 simultaneous doses of energy to the patient’s plaque PURPOSETo minimize number of treatments to clearance USEDose allows provider to determine blister thresho

  17. Slide 17: Current Clinical Protocol: 8N6 Protocol

    Current Clinical Protocol For Optimal Patient Outcomes: 8N6 Protocol 01 Twice a week: Minimum 8 visits in 6 weeks 02 Starting dose of at least 300 mj 03 Increase Dose over Time 04 Patient Returns: At least 8 visits per patient 05 …and management of the database to track results 17

  18. Slide 18: Maximizing Partner Clinical Revenue

    Maximizing Partner Clinical Revenue Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost/tx x recurrence factor 18

  19. Slide 19: Opportunity: Improving Clinical Delivery to Increase Revenue by Over 50%

    Opportunity: Improving Clinical Delivery to Increase Revenue by Over 50% Clinical Outcomes* Currently 40% of all patients treated have a regimen that provides NO clinical resultAdding all patients to 8N6 will increase Company revenue by $5.4M annually ($7k/account) Retention Rates*Current Patient Re

  20. Slide 20: Opportunity: Turnaround to Growth

    During 2.5 years (owned by PhotoMedex), XTRAC recurring businessRevenue grew by 317% from $8.4 to $26.5 millionGross Margin grew from 39% to 68%Consigned Installed base grew by 382 (from 268 to 650)Average Treatment Revenue/device/qtr grew from $5K to $11KPatient acquisition cost ranged $450-500/app

  21. Slide 21: Financial Profile

    STRATA 10-k Annual Report; Dec 31, 2017 Financial Profile Shares and Share Equivalents – Market cap*- $75M (As of June 8, 2018) * On an as converted basis of the convertible preferred stock** Does not include warrants as of December 31, 2017 of 2,406,625 with a weighted average strike price of $5.52

  22. Slide 22: STRATA Investment Highlights

    STRATA Investment Highlights Seasoned Management Team – Experienced in the BusinessDr. Dolev Rafaeli, CEO returns with the Accelmed transaction Excimer Laser Technology for DermatologyPsoriasis, Vitiligo, Eczema, Atopic Dermatitis and Leukoderma Large Market Opportunity Over 35 Million patients in t

  23. Slide 23: June 2018 Driving Value to Dermatology Partners

    June 2018 Investor Presentation Driving Value to Dermatology Partners Matching Patients and Clinics

STRATA Skin Sciences — Investor Presentation (June 2018) on 6ix